Trials / Recruiting
RecruitingNCT06897475
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3457263 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2025-03-28
- Primary completion
- 2026-12-01
- Completion
- 2027-01-01
- First posted
- 2025-03-27
- Last updated
- 2026-04-17
Locations
61 sites across 6 countries: United States, Canada, Germany, Poland, Puerto Rico, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06897475. Inclusion in this directory is not an endorsement.